Cargando…

Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs

BACKGROUND: The prevalence of dyslipidemia in China is increasing annually. Current studies suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies, while recent studies suggest that serum lipids influence the response rates of chronic hepatitis B (CHB) patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Ziqiang, Zheng, Juzeng, Zheng, Liang, Zheng, Endian, Zou, Zhuolin, Sheng, Xiong, Wu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557562/ https://www.ncbi.nlm.nih.gov/pubmed/34717643 http://dx.doi.org/10.1186/s12944-021-01582-x

Ejemplares similares

Alginate Suppresses Liver Fibrosis Through the Inhibition of Nuclear Factor-κB Signaling
por: Xia, Ziqiang, et al.
Publicado: (2020)

Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatitis via regulating iron metabolism
por: Xia, Ziqiang, et al.
Publicado: (2023)

Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein
por: Zheng, Juzeng, et al.
Publicado: (2021)

Low-level viremia in nucleoside analog-treated chronic hepatitis B patients
por: Zhang, Qian, et al.
Publicado: (2021)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Hepatitis B e Antigen Seroconversion Is Related with the Function of Dendritic Cells in Chronic Hepatitis B Virus Infection
por: Lin, Chunjing, et al.
Publicado: (2014)

Antiviral nucleoside analogs
por: Kataev, Vladimir E., et al.
Publicado: (2021)

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein
por: Zheng, Juzeng, et al.
Publicado: (2017)

Nucleoside Analogs with Fleximer Nucleobase
por: Chudinov, Mikhail V.
Publicado: (2020)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
por: Cai, Shaohang, et al.
Publicado: (2018)

Seroconversion of hepatitis B surface antigen among those with previously successful immune response in Southern China
por: Zheng, Zhigang, et al.
Publicado: (2020)

Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore
por: Thilakanathan, Cynthuja, et al.
Publicado: (2022)

Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B
por: Chi, Xiu-Mei, et al.
Publicado: (2021)

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record
por: Shi, Zongqi, et al.
Publicado: (2022)

Repurposing Nucleoside Analogs for Human Coronaviruses
por: Zandi, Keivan, et al.
Publicado: (2020)

Adherence to Treatment with Oral Nucleoside/Nucleotide Analogs in Patients with Chronic Hepatitis B
por: Ozyigitoglu, Derya, et al.
Publicado: (2022)

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog
por: Ji, Xin, et al.
Publicado: (2020)

New insights into the synergism of nucleoside analogs with radiotherapy
por: Lee, Michael W, et al.
Publicado: (2013)

Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants
por: Lam, Angela M., et al.
Publicado: (2017)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis
por: Bi, Jingfeng, et al.
Publicado: (2017)

Association between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children
por: Komatsu, Haruki, et al.
Publicado: (2014)

Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis
por: Cheng, Maoyuan, et al.
Publicado: (2020)

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
por: Shang, Jin, et al.
Publicado: (2021)

UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy
por: Liang, Kung-Hao, et al.
Publicado: (2016)

Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
por: Borbone, Nicola, et al.
Publicado: (2021)

Nucleoside Analog-treated Chronic Hepatitis B Patients showed Reduced Expression of PECAM-1 Gene in Peripheral Blood Mononuclear Cells in Bangladesh
por: Sultana, Nusrat, et al.
Publicado: (2014)

Diverse models for anti-HIV activity of purine nucleoside analogs
por: Khatri, Naveen, et al.
Publicado: (2015)

The nucleoside analog clitocine is a potent and efficacious readthrough agent
por: Friesen, Westley J., et al.
Publicado: (2017)

Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs
por: Gmeiner, William H.
Publicado: (2019)

Synthesis of Sugar and Nucleoside Analogs and Evaluation of Their Anticancer and Analgesic Potentials
por: Hussain, Fahad, et al.
Publicado: (2022)

Nucleoside Analogs: A Review of Its Source and Separation Processes
por: Wang, Pan, et al.
Publicado: (2023)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy
por: NISHIKAWA, HIROKI, et al.
Publicado: (2013)

Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study
por: Hsiao, Liang-Tsai, et al.
Publicado: (2015)

Identification of Structural and Molecular Features Involved in the Transport of 3′-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3
por: Rahman, MD Fazlur, et al.
Publicado: (2018)

Evaluation of Nucleoside Analogs as Antimicrobials Targeting Unique Enzymes in Borrelia burgdorferi
por: Chakraborti, Monideep, et al.
Publicado: (2020)

Structural Insights Into Tautomeric Dynamics in Nucleic Acids and in Antiviral Nucleoside Analogs
por: Fedeles, Bogdan I., et al.
Publicado: (2022)

Nucleoside analogs in ADAR guide strands targeting 5′-UA̲ sites
por: Brinkman, Hannah F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_66i22g0pj6f50pdhr6npqdb4m6